Skip to content

Pasadena Star News

46°F
Thursday, February 19th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

215.43 -0.10 (-0.05%)
Streaming Delayed Price Updated: 3:15 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
From Natera, Inc.
Via Business Wire
News headline image
Natera Submits Signatera™ CDx PMA to FDA
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
From Natera, Inc.
Via Business Wire
News headline image
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
From Natera, Inc.
Via Business Wire
News headline image
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
From Natera, Inc.
Via Business Wire
News headline image
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
From Natera, Inc.
Via Business Wire
News headline image
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
From Natera, Inc.
Via Business Wire
News headline image
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
From Natera, Inc.
Via Business Wire
News headline image
Natera Acquires Foresight Diagnostics
From Natera, Inc.
Via Business Wire
News headline image
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
From Natera, Inc.
Via Business Wire
News headline image
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
From Natera, Inc.
Via Business Wire
News headline image
Natera Integrates with Flatiron Health’s OncoEMR® Platform
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Third Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its Third Quarter Results on November 6, 2025
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
From Natera, Inc.
Via Business Wire
News headline image
Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.